Phase 1 × Recruiting × Lymphoma, Large B-Cell, Diffuse × Clear all Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Phase 1 Recruiting
32 enrolled
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
572 enrolled
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Phase 1 Recruiting
20 enrolled
Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma
Phase 1 Recruiting
56 enrolled
P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies
Phase 1 Recruiting
120 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Phase 1 Recruiting
55 enrolled
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
15 enrolled
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Phase 1 Recruiting
25 enrolled
PRODIGY
Phase 1 Recruiting
10 enrolled
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1 Recruiting
60 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Phase 1 Recruiting
150 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
20 enrolled
Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 Recruiting
30 enrolled
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma
Phase 1 Recruiting
165 enrolled
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Phase 1 Recruiting
154 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
ON-5001
Phase 1 Recruiting
168 enrolled
SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1 Recruiting
18 enrolled
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 Recruiting
24 enrolled
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Phase 1 Recruiting
60 enrolled
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Phase 1 Recruiting
140 enrolled
A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 Recruiting
345 enrolled
CARLOTTA01
Phase 1 Recruiting
16 enrolled
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Phase 1 Recruiting
15 enrolled
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
37 enrolled
Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)
Phase 1 Recruiting
10 enrolled
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Phase 1 Recruiting
56 enrolled
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Phase 1 Recruiting
15 enrolled
Tazemetostat and Venetoclax in Relapsed/Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
38 enrolled
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Phase 1 Recruiting
248 enrolled
CD19-CARNK/T
Phase 1 Recruiting
52 enrolled
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Phase 1 Recruiting
33 enrolled
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Phase 1 Recruiting
25 enrolled
An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase 1 Recruiting
9 enrolled
ASHA-1
Phase 1 Recruiting
40 enrolled
CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL
Phase 1 Recruiting
24 enrolled